Software developed by Oxford e-Research Centre in collaboration with C4X Discovery Limited and the Mathematical Institute should reduce the time taken to develop new drugs for complex disorders such as Parkinson’s disease.
Obtaining regulatory approval for a new drug is not only costly, but can take up to 10 years. The process is tricky and fails around 90% of the time. The success rate can be dramatically increased, even doubled using genetic evidence, however, it is extremely difficult to understand the genetic basis of complex disorders such as Parkinson’s disease and diabetes. In Parkinson’s, for example, 70% of the ‘genetic load’ – the proportion that an illness is due to genetic rather than environmental factors – is unexplained. Conventional analysis generates limited information and insights, often identifying just one significant gene variable. The onset of complex disorders is thought to rely on the interaction of many variables, something not examined by these traditional methods.
C4X Discovery Holdings PLC (LON:C4XD) is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics.
